RNAConnect specializes in advanced enzymatic technologies that enhance RNA research and applications across various fields, including diagnostics and gene therapy. Their flagship product, UltraMarathonRT™ (uMRT), is a next-generation reverse transcriptase designed to provide comprehensive insights into complex RNA landscapes. This enzyme excels in synthesizing complementary DNA (cDNA) from RNA, particularly in challenging scenarios involving low-abundance or highly structured RNA. The uMRT's unique properties, such as its intrinsic helicase activity, allow it to efficiently unwind complex RNA structures without compromising sample integrity, making it suitable for applications in discovery research, gene expression studies, and quality control in RNA therapies.

In addition to the uMRT, RNAConnect offers the UltraMarathonRT Template Switching Kit, which facilitates library preparation for RNA sequencing applications. This kit is engineered to produce full-length cDNAs while minimizing bias, making it ideal for bulk sequencing and low-abundance RNA samples. The combination of uMRT with the Template Switching Oligo (TSO) enables researchers to create high-quality cDNA libraries, essential for accurate sequencing and analysis. Overall, RNAConnect's innovative technologies are positioned to significantly advance the capabilities of RNA research and its applications in clinical diagnostics and therapeutic development.

United States

RNAConnect, Inc. is a company focused on the development of life science reagents to help further RNA sciences. They promise groundbreaking solutions for exploring the real-world diversity of RNA sequence and structure.

RNAConnect

Company Details